Quick Answer
AVENUE THERAPEUTICS, INC. reported Stockholders Equity of $1.83 million for the year ending 2025.
- AVENUE THERAPEUTICS, INC. showed a decrease of -34.5% in Stockholders Equity from 2024 to 2025.
- This data is from AVENUE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2015 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$8.90 million | Q2 2017: $27.16 million | Q3 2017: $24.19 million | Q1 2018: $9.35 million | Q2 2018: $5.02 million | Q3 2018: $2.79 million | Q1 2019: $20.35 million | Q2 2019: $13.90 million | Q3 2019: $11.96 million | Q1 2020: $5.77 million | Q2 2020: $4.10 million | Q3 2020: $3.23 million | Q4 2020: $2.36 million | Q1 2021: $1.48 million | Q2 2021: $642.0 thousand | Q3 2021: -$160.0 thousand | Q1 2022: $1.16 million | Q2 2022: $598.0 thousand | Q3 2022: -$39.0 thousand | Q1 2023: -$1.45 million | Q2 2023: -$5.34 million | Q3 2023: -$3.65 million | Q1 2024: $2.84 million | Q2 2024: $4.76 million | Q3 2024: $2.61 million | Q1 2025: $3.51 million | Q2 2025: $4.06 million | Q3 2025: $3.56 million.
- Historical annual values: Fiscal year 2025: $1.83 million | Fiscal year 2024: $2.80 million | Fiscal year 2023: $1.58 million | Fiscal year 2022: $3.91 million | Fiscal year 2021: $3.45 million | Fiscal year 2020: $2.36 million | Fiscal year 2019: $6.80 million | Fiscal year 2018: -$631.0 thousand | Fiscal year 2017: $19.38 million | Fiscal year 2016: -$8.25 million | Fiscal year 2015: -$5.14 million | Fiscal year 2015: $0.00.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: